Realization of humoral immunity against SARS-CoV-2 infections.
作者信息
Lin Yong, Zhao Zhenyu, Zheng Jiaxin, Liu Jia, Huang Ailong
机构信息
Key Laboratory of Molecular Biology of Infectious Diseases (Chinese Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, No.1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China.
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
Fundam Res. 2021 Mar;1(2):186-188. doi: 10.1016/j.fmre.2021.01.008. Epub 2021 Jan 22.
Abstract
摘要
相似文献
1
Realization of humoral immunity against SARS-CoV-2 infections.实现针对新型冠状病毒肺炎感染的体液免疫
Fundam Res. 2021 Mar;1(2):186-188. doi: 10.1016/j.fmre.2021.01.008. Epub 2021 Jan 22.
2
A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.长达10年的针对中东呼吸综合征冠状病毒（MERS-CoV）的细胞免疫和体液免疫可交叉识别严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的野生型和变体：MERS-CoV对泛冠状病毒疫苗的一种潜在单向交叉保护作用。
J Med Virol. 2025 Jan;97(1):e70071. doi: 10.1002/jmv.70071.
3
4
Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.阿根廷卫生保健工作者对 SARS-CoV-2 免疫力的纵向随访：接种卫星 V 疫苗后体液反应和中和能力的持久性。
mSphere. 2023 Jun 22;8(3):e0066222. doi: 10.1128/msphere.00662-22. Epub 2023 Apr 18.
5
Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.完全接种疫苗的个体中体液和细胞免疫应答，无论是否发生 SARS-CoV-2 突破感染：来自 CoV-ADAPT 队列的结果。
J Med Virol. 2023 Oct;95(10):e29122. doi: 10.1002/jmv.29122.
6
Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.评估针对 SARS-CoV-2 的体液免疫：蚀斑减少中和试验的验证和常规及替代中和测定法的多实验室比较。
Microbiol Spectr. 2021 Dec 22;9(3):e0088621. doi: 10.1128/Spectrum.00886-21. Epub 2021 Nov 17.
7
Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.恢复期儿童和青少年的 SARS-CoV-2 体液 VOC 交叉反应性减弱和持续的细胞免疫。
BMC Infect Dis. 2023 Nov 22;23(1):818. doi: 10.1186/s12879-023-08805-9.
8
Robust memory humoral immune response to SARS-CoV-2 in the tonsils of adults and children.成人和儿童扁桃体中对 SARS-CoV-2 的强大记忆体液免疫反应。
Front Immunol. 2023 Dec 11;14:1291534. doi: 10.3389/fimmu.2023.1291534. eCollection 2023.
9
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.SARS-CoV-2 的早期进化与跨冠状病毒免疫。
mSphere. 2020 Sep 2;5(5):e00622-20. doi: 10.1128/mSphere.00622-20.
10
Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.SARS-CoV-2 特异性体液免疫的特性及其潜在的应用和治疗前景。
Cell Mol Immunol. 2022 Feb;19(2):150-157. doi: 10.1038/s41423-021-00774-w. Epub 2021 Oct 13.
本文引用的文献
1
Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后中和抗体反应的纵向动力学。
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539. doi: 10.1093/cid/ciaa1143.
2
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.恒河猴初次接触 SARS-CoV-2 可预防再次感染。
Science. 2020 Aug 14;369(6505):818-823. doi: 10.1126/science.abc5343. Epub 2020 Jul 2.
3
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
4
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.新型冠状病毒感染恢复期个体中 SARS-CoV-2 特异性体液和细胞免疫的检测。
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
5
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎（COVID-19）患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
Zotero 插件